At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,195 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma - a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population
In Brief
An observational study for Asthma and Smoking. Completed, enrolled 7,195 participants.
Detailed Summary
To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone (EF HFA-BDP) and other inhaled corticosteroid (ICS) therapy commonly used in the UK, specifically fluticasone (FP) and non-extrafine (NEF) BDP (CFC-BDP and NEF HFA-BDP) in a UK primary care asthma population of current smokers.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
CollaboratorsTeva Branded Pharmaceutical Products R&D, Inc.
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
Primary CompletionJun 2012
First PostedNov 2012
TodayJul 2026
First PostedNov 20, 2012
Enrollment StartNov 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.6 years ago